Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA
Buy
Sell